fbpx

Trials for treatment of aggressive tumors gets FDA nod

Cris Collingwood//May 2, 2023

Trials for treatment of aggressive tumors gets FDA nod

Cris Collingwood//May 2, 2023

Hummelstown-based SIRPant Immunotherapeutics, Inc., said the U.S. Food and Drug Administration has cleared its investigational new drug (IND) application for its SIRPant-M. 

The clinical-stage biopharmaceutical company said SIRPant-M is a therapy for the treatment of aggressive tumors. 

 Under the application, SIRPant intends to begin a study in patients with relapsed refractory non-Hodgkin lymphoma in the third quarter of this year. 

“This is a major accomplishment for the company and an important step forward in the clinical evaluation of SIRPant-M for the treatment of multiple tumor types,” said Robert Towarnicki, president and CEO.  

Towarnicki added that the initial study will enroll relapsed patients who are ineligible for or previously failed approved treatments. 

SIRPant anticipates following this initial IND with a second IND for SIRPant-M focused on solid tumor treatments, initially targeting head and neck cancers. In preclinical testing, SIRPant-M has shown effectiveness against a wide variety of solid tumors in the body, in addition to compelling positive data in hematological tumors, the company said. 

“Leveraging recent findings in macrophage biology, we developed a first-in-class cell therapy, SIRPant-M, to initiate adaptive immune responses against cancerous cells without requiring prior cancer-associated antigen identification” said Nathanael McCurley, vice president, R&D. 

The company said it anticipates conducting the planned clinical trial at five sites across the United States.  

=